Amgen (AMGN) Tepezza Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Amgen (AMGN) Tepezza Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease

TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE

September 24, 2024 4:00 PM EDT

THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity... More